The present invention relates to biomarkers that are predictive of renal disease in patients who have diabetes. The present invention also provides methods of using such biomarkers to predict the risk that a diabetic patient will develop renal disease, and/or to identify a patient who has diabetes as being in need of a therapy to prevent or delay the onset of a renal disease.

Methods and compositions for risk detection, early diagnosis, prognosis, and monitoring of sleepiness in an individual by measuring the amount of specific biomarkers present in a bodily fluid and comparing them to a reference level of biomarkers in a sample from a healthy person, a person previously diagnosed with sleepiness, or an earlier sample from the individual of interest.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Disclosed are methods for determining the presence of one or more proteins in a sample, the methods comprising: enzymatically digesting the sample with a protease activity to generate a plurality of proteolytic peptides; separating the plurality of proteolytic peptides using liquid chromatography; performing mass spectrometry on the separated plurality of peptides; and wherein a protein is present in the sample when three or more target peptides for the protein are present among the proteolytic peptides; and wherein the target peptides are selected from the groups consisting of SEQ ID NOS:6-8, SEQ ID NOS:9-11, SEQ ID NOS:12-14, SEQ ID NOS:15-17, and SEQ ID NOS:18-20. In embodiments, a known quantity of a standard peptide may be added to the proteolytic peptides.

A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target in vitro or ex vivo cell population; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said target cell population or one or more cells and/or compounds present in said target cell population.

A microwave microstrip resonator apparatus including a housing; a resonator within the housing; an output conductor within the housing and spaced apart from the resonator so as to define a capacitive gap therebetween; a reaction vessel configured to reside with the capacitive gap; and a power supply coupled to the resonator whereby contents within the reaction vessel are heated when energy is supplied to the resonator by the power supply. A mass spectrometer may also be coupled to an outlet end of the reaction vessel such that the contents within the reaction vessel are, simultaneously, delivered to the mass spectrometer for analysis.

Provided herein are methods for preparing biological samples for spatial proteomic analysis, methods of determining a location of a protein analyte in a biological sample, and methods of determining a location of a protein analyte and a nucleic acid analyte in a biological sample.

The invention relates to a method for the determination and visualization of the spatial distribution of tissue states of a tissue sample, wherein a mass/mobility map is acquired at each of a plurality of sample sites of the tissue sample, the signal heights at each sample site are determined at characteristic signal positions in the corresponding mass/mobility map, from which a tissue state for each sample site is calculated with the aid of a mathematical/statistical classification algorithm, and the spatial distribution of the tissue states calculated for the sample sites is represented graphically.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

Apparatus and methods for the detection of proteins in biological fluids such as urine using a label-free assay is described. Specific proteins are detected by their binding to highly specific capture reagents such as SOMAmers that are attached to the surface of a substrate. Changes to these capture reagents and their local environment upon protein binding modify the behavior of color centers (e.g., fluorescence, ionization state, spin state, etc.) embedded in the substrate beneath the bound capture reagents. These changes can be read out, for example, optically or electrically, for an individual color center or as an average response of many color centers.